This article describes a new Stata command called simontwostage, which calculates the critical values and sample sizes for two-stage designs for phase II oncology trials. Options are provided to determine the minimax and optimal designs proposed by Simon (1989, Controlled Clinical Trials 10: 1–10) and admissible designs described by Jung et al. (2004, Statistics in Medicine 23: 561–569). Furthermore, nonstochastic and stochastic curtailment rules can be implemented in both stages of the trial, and the properties of the curtailed designs can be examined.
AyanlowoA. O., and ReddenD. T.2007. Stochastically curtailed phase II clinical trials. Statistics in Medicine26: 1462–1472.
2.
BryantJ., and DayR.1995. Incorporating toxicity considerations into the design of two-stage phase II clinical trials. Biometrics51: 1372–1383.
3.
ChangM. N., TherneauT. M., WieandH. S., and ChaS. S.1987. Designs for group sequential phase II clinical trials. Biometrics43: 865–874.
4.
ChenT. T.1997. Optimal three-stage designs for phase II cancer clinical trials. Statistics in Medicine16: 2701–2711.
5.
GreenS. J., and DahlbergS.1992. Planned versus attained design in phase II clinical trials. Statistics in Medicine11: 853–862.
6.
JungS.-H., LeeT., KimK., and GeorgeS. L.2004. Admissible two-stage designs for phase II cancer clinical trials. Statistics in Medicine23: 561–569.
7.
KunzC. U., and KieserM.2011. Non-stochastic and stochastic curtailment in phase II oncology trials. Working paper.
8.
KunzC. U. Forthcoming. Optimal two-stage designs for single-arm phase II oncology trials with two binary endpoints. Methods of Information in Medicine.http://www.ncbi.nlm.nih.gov/pubmed/21057719.
9.
LinS. P., and ChenT. T.2000. Optimal two-stage designs for phase II clinical trials with differentiation of complete and partial responses. Communications in Statistics—Theory and Methods29: 923–940.
10.
LinX., AllredR., and AndrewsG.2008. A two-stage phase II trial design utilizing both primary and secondary endpoints. Pharmaceutical Statistics7: 88–92.
11.
LinY., and ShihW. J.2004. Adaptive two-stage designs for single-arm phase IIA cancer clinical trials. Biometrics60: 482–490.
12.
LuY., JinH., and LambornK. R.2005. A design of phase II cancer trials using total and complete response endpoints. Statistics in Medicine24: 3155–3170.
13.
ManderA.2009. simon2stage: Stata module to compute the design parameters for a Simon two-stage design. Statistical Software Components S457081, Department of Economics, Boston College. http://ideas.repec.org/c/boc/bocode/s457081.html.
14.
ManderA. P., and ThompsonS. G.2010. Two-stage designs optimal under the alternative hypothesis for phase II cancer clinical trials. Contemporary Clinical Trials31: 572–578.
15.
PanageasK. S., SmithA., GüonenM., and ChapmanP. B.2002. An optimal two-stage phase II design utilizing complete and partial response information separately. Controlled Clinical Trials23: 367–379.
16.
ShusterJ.2002. Optimal two-stage designs for single arm phase II cancer trials. Journal of Biopharmaceutical Statistics12: 39–51.
17.
SimonR.1989. Optimal two-stage designs for phase II clinical trials. Controlled Clinical Trials10: 1–10.